Kaylea Boutwell
Interventional Pain Medicine · Chesterfield, MONPI 1144425083
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,716 of the $5,263 with a category attached, or 70.6%. 29 manufacturers reported payments, led by Abbott at 46.6% of the total. Reporting peaked in 2023 at $2,286 and has fallen 92.7% since, to $168 in 2025.
Across 174 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AbbVie$932
- Nevro Corp.$306
- IBSA Pharma Inc.$246
- Boston Scientific$186
- Scilex Pharmaceuticals Inc.$168
- plus $971 from 23 others
What the payments were for
- Travel & lodging$1,52129%
- Food & beverage$3,71671%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $2,454 |
| AbbVie(2 entities) | 68 | $932 |
| Nevro Corp. | 3 | $306 |
| IBSA Pharma Inc. | 12 | $246 |
| Boston Scientific | 2 | $186 |
| Scilex Pharmaceuticals Inc. | 9 | $168 |
| SPR Therapeutics, Inc | 1 | $130 |
| MML US, Inc. | 3 | $118 |
| Tersera Therapeutics LLC | 5 | $87 |
| Azurity Pharmaceuticals, Inc. | 5 | $75 |
| Elite Orthopedics, LLC | 2 | $74 |
| Amgen | 5 | $69 |
| Lilly USA, LLC | 3 | $56 |
| Vertex | 2 | $41 |
| Medtronic | 2 | $38 |
| Pfizer | 2 | $36 |
| Arthrex | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Averitas Pharma Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $25 |
| Novartis | 1 | $22 |
| Electronic Waveform Lab, Inc. | 2 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Shionogi Inc | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Kaleo, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$1,649
- Omnia$150
- Senza Spinal Cord Stimulation System$141
- Proclaim Family of SCS IPGs$136
- SPRINT PNS System$130
- BOTOX$125
- GENERAL - THERAPIES$107
- Proclaim IPG$102
How this compares
$5,263 in reported general payments places this provider in the 55th percentile of 27 interventional pain medicine providers in Missouri.
See all interventional pain medicine providers in Missouri →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 26 | $1,731 |
| Gabapentin | 43 | $655 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $569 |
| Amitriptyline Hcl | 29 | $540 |
| Duloxetine Hcl | 16 | $302 |
| Baclofen | 18 | $212 |
| Cyclobenzaprine Hcl | 14 | $115 |
| Tizanidine Hcl | 17 | $99 |
| Tramadol Hcl | 14 | $53 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Chesterfield
- Helen BlakeChesterfield$48K
- Armin RahimiChesterfield$20
- Rebecca SandersJoplin$209K
- Ramis GheithBridgeton$73K
- Andrew FrazierKansas City$32K
- Christian OliverBridgeton$18K
- David TonkinSpringfield$14K
- Dwayne JonesKansas City$11K
- Bradford NobleColumbia$8K
- Calvin CajigalDes Peres$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.